Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure

Antimicrob Agents Chemother. 2005 Aug;49(8):3550-3. doi: 10.1128/AAC.49.8.3550-3553.2005.

Abstract

The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Bacterial Agents* / administration & dosage
  • Anti-Bacterial Agents* / pharmacokinetics
  • Anti-Bacterial Agents* / therapeutic use
  • Ceftazidime* / administration & dosage
  • Ceftazidime* / pharmacokinetics
  • Ceftazidime* / therapeutic use
  • Female
  • Fever / drug therapy*
  • Fever / microbiology
  • Humans
  • Infusions, Intravenous
  • Leukemia, Myeloid, Acute / complications
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Neutropenia / complications
  • Neutropenia / drug therapy*
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects

Substances

  • Anti-Bacterial Agents
  • Ceftazidime